Theranexus SA

THX Pharma Société Anonyme is a biopharmaceutical company that develops drug candidates for central nervous system disorders. Its pipeline includes Batten-1, in Phase 1/2 clinical study for a rare neurological disease, and TX01 for Gaucher disease and Niemann-Pick type C disease. The company was formerly known as Theranexus Société Anonyme and changed its name to THX Pharma Société Anonyme in September 2025. Founded in 2013, it is headquartered in Lyon, France.